Treatment of the breast cancer cells with increasing concentrations of trastuzumab, anti-HER-2 biosimilars, and the novel anti-HER-2001 × HBsAg biomolecules was followed by pulsing with thymidine marked with tritium. Here, ERBB2 is linked to breast carcinoma.